The 36th Annual Meeting of the European Association of Nuclear Medicine (EANM) will be held in Vienna, Austria from September 9th to 13th, 2023.

The EANM Annual Meeting is the world’s most valuable nuclear medicine conference, attracting thousands of professionals from around the world in the fields of nuclear medicine, nuclear pharmacy, molecular imaging, precision diagnostic equipment, and related areas.

This year, EANM has highlighted the exponential growth in the field of nuclear medicine, with increasing attention being paid to targeted radionuclide therapy, nuclear imaging (including PET and SPECT imaging), and artificial intelligence. More innovative content is also gaining importance. As Europe is the birthplace of nuclear medicine, it places significant emphasis on collaboration with stakeholders outside of Europe. Due to the changing competitive landscape, the market’s demand for quality in the nuclear medicine industry is increasing, leading to higher industry certification requirements. The development of the nuclear medicine industry requires unity among the industry and research communities to drive progress collectively.

Suzhou Four Health Pharmaceuticals Co., Ltd., as a China-US-Europe joint nuclear medicine innovation company, has outstanding advantages in scientific discovery and business integration. Upon official invitation from EANM, Professor Weibo CAI, Chief Scientific Officer of the US company, and Professor Hao HONG, Chief Technology Officer of Suzhou Four Health Pharmaceuticals Co., Ltd., delivered featured presentations at the 2023 Annual Congress of the European Association of Nuclear Medicine.

Professor Weibo CAI, Fellow of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Fellow of the American Institute for Medical and Biological Engineering (AIMBE), Fellow of the Royal Society of Chemistry (RSC), and Lifetime Professor at the University of Wisconsin-Madison, is renowned for his outstanding achievements in radiology, medical physics, materials science and engineering, and pharmaceutical sciences.

Professor Weibo CAI has extensive academic experience in radionuclide labeling and targeted diagnostics and therapeutics of monoclonal antibodies, nanobodies, engineered antibodies (diabody, scFv, Fab, F(ab’)2, etc.), and antibody conjugates. This has provided solid technical support for the pipeline development of the company.

In his presentation at this congress,  Professor Weibo CAI summarized various cutting-edge technologies for molecular imaging of the immune system. His presentation was titled “Molecular Imaging of the Immune System”, in which he also demonstrated his many years of experience in radionuclide diagnostics and therapeutics targeting the immune system.

In addition, during the EANM Annual Meeting, Professor Weibo CAI was invited by Professor Arturo Chiti, editor-in-chief of EJNMMI, to serve as one of the moderators for a 90-minute session titled “You, the EANM, and EJNMMI”. He co-hosted this session with Professor Xiao-Li Lan, Director of the Department of Nuclear Medicine at Wuhan Union Hospital, and Professor Cristina Müller from ETH Zurich. During this session, Professor CAI and the other two moderators, together with Ignasi Carrio (former editor-in-chief of EJNMMI, Barcelona, Spain), Arturo Chiti (current editor-in-chief, Milan, Italy), Mike Sathekge (winner of the EJNMMI Most-cited paper, South Africa), and the audience, discussed the development history of EJNMMI and shared their perspectives on its future development plans. The atmosphere of the discussion was highly engaging.

As a young talent introduced to China under the National Major Talent Program and an innovative and entrepreneurial talent from Jiangsu Province, Professor Hong Hao has won multiple awards in the field of nuclear drug research during his studies and work in the United States. The content of this report is “computer-assisted development of Trop-2 targeted polypeptide and its application in radionuclide diagnosis and treatment of pancreatic cancer (OP-212)”. This presentation was also highly rated and one of the top talks in the “Novel Cancer Imaging Targets” session.

Professor Hao HONG said that attending the annual meeting was an important presentation of Four Health’s pipeline to the world’s top nuclear medicine/nuclear pharmacy researchers, as well as a test. In his report, he showed that Fourt Health innovatively obtained a series of peptides with subnanomolar targeting ability to the tumor highly expressed protein Trop-2 for the first time, and combined with diagnostic and therapeutic radionuclides (copper-64 and lutetium-177), successfully performed targeted diagnosis and treatment of pancreatic tumors.

Dr. Guanli WANG, CEO of Suzhou Four Health Pharmaceuticals Technology Co., Ltd., attended the EANM annual meeting throughout. Dr. Guanli WANG has been immersed in the nuclear medicine and nuclear technology industry for more than 10 years and has many partners in the United States and Europe. At the annual meeting, Dr. Guanli WANG communicated with his partners more deeply for the first time as a nuclear medicine R&D entrepreneur, reached a number of cross-border strategic cooperation, and formed a global development strategy pattern of Suzhou Four Health Pharmaceuticals Technology Co., Ltd. with the joint resources of China, the United States and Europe.

Dr. Guanli WANG noted that this EANM congress broke records for the most academic presentations/abstracts (over 2,000) and attendees (over 7,700), reflecting Europe and the US’s continued global leadership in targeted radionuclide therapy. As a nuclear medicine innovation company in China, Four Health still needs to learn more from the development experience and success of advanced companies in Europe and the US, and combine it with China’s national conditions to pave our own way of R&D and exploration in the field of nuclear medicine as a Chinese company.

The European Association of Nuclear Medicine (EANM) was founded in 1985 and is the largest non-profit nuclear medicine organization in Europe. The vision of EANM is to optimize and advance the science and education of nuclear medicine for the benefit of humankind. The goal of EANM is to provide a platform for disseminating and discussing the latest achievements in the field of nuclear medicine, including multimodality imaging and related topics. EANM has over 9,000 members from more than 80 countries in Europe and worldwide, including physicians, scientists, technologists, and other professionals working in the field of nuclear medicine or related areas.